arrow
N

Nobuhiro Kanaji

Kagawa University
H指数:22
被引数:1,744

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Treatment sequence after first-line immunotherapy in older adults with advanced NSCLC (NEJ057)

老年晚期非小细胞肺癌患者一线免疫治疗后治疗方案(NEJ057)

2026-10-030
PRE
Incidence and clinical features of venous thromboembolism in patients with lung cancer in Japan: results from the CS-Lung-003 prospective observational registry study

日本肺癌患者中静脉血栓栓塞症的发病率和临床特征:CS-Lung-003前瞻性观察性登记研究的结果

2025-11-010
OAAI
The clinical potential of HMGB1 for the risk assessment of severe checkpoint inhibitor pneumonitis: A prospective multicenter study (CS-Lung004)

HMGB1在重度检查点抑制剂肺炎风险评估中的临床潜力:一项前瞻性多中心研究(CS-Lung004)

2025-07-050
OA
Ramucirumab and erlotinib combination as first-line treatment for advanced or recurrent non-small cell lung cancer harboring EGFR Exon21 L858R mutation: a multicenter retrospective observational cohort study in Japan (REAL-SPEED)

Ramucirumab与erlotinib联合作为携带<i>EGFR</i>外显子21 L858R突变的晚期或复发非小细胞肺癌的一线治疗:一项在日本进行的多中心回顾性观察队列研究(REAL-SPEED)。

2025-06-160
OA
Immunotherapy With Radiotherapy for Brain Metastases in Patients With NSCLC: NEJ060

NSCLC患者脑转移瘤放疗免疫治疗: NEJ060

2024-04-013
OA
Association of longer telomere length in cancer cells and cancer-associated fibroblasts with worse prognosis
2022-12-264
PRE
The significance of ultra-low EGFR T790M mutations on EGFR-TKI efficacy in patients with NSCLC -the WJOG13119L study
2022-07-010
OAAI
Phosphorylation of hTERT at threonine 249 is a novel tumor biomarker of aggressive cancer with poor prognosis in multiple organs
2022-03-239
OA
A phase II study of S-1 and cisplatin with concurrent thoracic radiotherapy followed by durvalumab for unresectable, locally advanced non-small-cell lung cancer in Japan (SAMURAI study)
2021-02-272
OAAI
A Prospective Cohort Study to Define the Clinical Features and Outcome of Lung Cancers Harboring HER2 Aberration in Japan (HER2-CS STUDY)

一项前瞻性队列研究,以定义日本携带HER2畸变的肺癌的临床特征和结果 (HER2-CS研究)

CHEST
IF8.6
2019-08-0131
PREAI